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Autoimmune hemolytic anemia (AIHA) is characterized by immunemediated erythrocytes
destruction by autoantibodies with or without complement activation. Additional
pathologic mechanisms include cellular cytotoxicity, cytokline dysregulation, and
inadequate bone marrow compensation with fibrosis/dyserythropoiesis. The latter
resembles that of bone marrow failures, namely aplastic anemia and myelodysplastic
syndromes. Paroxysmal nocturnal hemoglobinuria (PNH) clones are increasingly
recognized in bone marrow failure syndromes, and their selection and expansion are
thought to be mediated by immune mechanisms. In this study, we aimed to evaluate the
prevalence of PNH clones in 99 patients with primary AIHA, and their correlations with
disease features and outcomes. Moreover, in the attempt to disclose the physiopathology
of PNH positivity in AIHA, serum levels of several immunomodulatory cytokines were
tested. A PNH clone was found in 37 AIHA patients (37,4%), with a median size of
0.2% on granulocytes (range 0.03–85). Two patients showed a large clone (16 and 85%)
and were therefore considered as AIHA/PNH association and not included in further
analysis. Compared to PNH negative, PNH positive cases displayed a higher hemolytic
pattern with adequate bone marrow compensation. AIHA type, response to therapy,
complications and outcome were comparable between the two groups. Regarding
cytokine levels, IFN-γ and IL-17 were lower in PNH positive vs. PNH negative AIHAs
(0.3 ± 0.2 vs. 1.33 ± 2.5; 0.15 ± 0.3 vs. 3,7 ± 9.1, respectively, p = 0.07 for both). In
PNH positive AIHAs, IFN-γ positively correlated with reticulocytes (r = 0.52, p = 0.01)
and with the bone marrow responsiveness index (r = 0.69, p = 0.002). Conversely,
IL-6 and IL-10 showed the same pattern in PNH positive and PNH negative AIHAs. IL-6
levels and TGF-β positively correlated with clone size (r = 0.35, p = 0.007, and r =
0.38, p = 0.05, respectively), as well as with LDH values (r = 0.69, p = 0.0003, and r
= 0.34, p = 0.07, respectively). These data suggest testing PNH clones in AIHA since
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their prevalence is not negligible, and may correlate with a prominent hemolytic pattern,
a higher thrombotic risk, and a different therapy indication. PNH testing is particularly
advisable in complex cases with inadequate response to AIHA-specific therapy. Cytokine
patterns of PNH positive and negative AIHAs may give hints about the pathogenesis of
highly hemolytic AIHA.
Keywords: warm autoimmune hemolytic anemia, cold agglutinin disease, paroxysmal nocturnal hemoglobinuria,
rituximab, cytokines
INTRODUCTION
Autoimmune hemolytic anemia (AIHA) is a clinically
heterogeneous disease ranging from mild/ compensated to
very severe life-threatening hemolysis (1, 2). Several pathogenic
mechanisms are involved, mainly encompassing autoantibodies
of different classes, thermal amplitude, and affinity/efficiency
in activating complement. Other factors include abnormalities
of antigen-presenting cells, increased antibody-dependent
cellular cytotoxicity (ADCC) and cytotoxic CD8+T cells,
aberrant cytokine production and inflammation, and alterations
of immunoregulatory T cells. While direct complement-
mediated lysis takes place mainly in the circulations and
liver, ADCC and phagocytosis occur preferentially in the
spleen and lymphoid organs (3). Finally, the efficacy of the
erythroblastic compensatory response can greatly influence the
clinical picture of AIHA (4–6). Intravascular hemolysis has
been shown to correlate with the rate of complement activation
and with the risk of AIHA related thrombosis. Bone marrow
compensation has been demonstated to contribute to anemia
severity at onset, the major predictor of disease relapse and
outcome. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare
(incidence of 2–6 per million) clonal acquired disease, whose
clinical spectrum includes both overt intravascular hemolysis
and bone marrow failure, namely aplastic anemia (AA) and
hypocellular myelodysplastic syndromes (MDS). PNH is due
to a somatic mutation of the hematopoietic stem cell involving
the PIG-A gene and resulting in deficiency of the complement
inhibitory GPI-anchored proteins CD55 and CD59 (7–9). PNH
has been classified by the International PNH Interest Group
(IPIG) (8, 10) in three clinical subgroups: classic, PNH in the
setting of another bone marrow disorder, and subclinical. The
classic form is dominated by intravascular hemolysis, with
markedly elevated LDH and a clone size >50%. The second
group, mainly AA or MDS associated, is clinically dominated
by the underlying bone marrow features and displays a clone
size 10–50%. The third category is defined as subclinical, since
there is no clinical or biochemical evidence of intravascular
hemolysis and the PNH clone is <10%. Since the last 10 years,
the increased sensitivity of the cytofluorimetric techniques (up
to ≥0.01% clone size) enabled the detection of small PNH clones
in up to 60% of AA and 30% of MDS (7–9, 11). The significance
of these clones is still unclear, with some evidences for better
response to immunosuppressive therapy in PNH positive cases.
These tests allowed the detection of small PNH populations
even in diseases not commonly associated to PNH such as
hypomegakaryocytic thrombocytopenia (12) and chronic
benign neutropenia (13). These forms are characterized by
both immune mediated peripheral cytopenia and bone marrow
failure, similarly to what demonstrated for AA and AIHA
itself. We therefore analyzed the presence of small PNH
clones in primary AIHA in order to evaluate their clinical
significance in this acquired hemolytic disease. Furthermore,
given that PNH typically arises in the context of autoimmune
activation, we investigated immunoregolatory and inflammatory
cytokines to address the role of PNH clones in the pathogenesis
of AIHA.
METHODS
Ninety-nine patients with primary AIHA tested at Fondazione
IRCCS Ca’ Granda Ospedale Policlinico of Milan from March
2001 until October 2019 were included in the analysis.
Demographic and clinical phenotypes were retrospectively
evaluated from August 2017 until January 2020.
Clinical history, blood counts, hemolytic markers,
AIHA type, bone marrow features, number and type of
therapeutic interventions and their response rates, occurrence
of complications (particularly thrombosis), and death
were collected.
Primary AIHA was defined by hemolytic anemia and positive
direct antiglobulin test (DAT), in the absence of associated
overt lymphoproliferative, infectious, autoimmune, or neoplastic
diseases. Patients were classified as wAIHA (DAT positive for IgG
or IgG+C), CAD (DAT positive for C only, with high titer cold
agglutinins), mixed (DAT positive for IgG+Cwith high titer cold
agglutinins) and atypical (DAT negative, DAT positive for IgA
only, warm IgM).
Reticulocytosis was evaluated and expressed as bone marrow
responsiveness index (BMRI: absolute reticulocyte count x
patient’ Hb/normal Hb) (1).
PNH Clone Testing
PNH testing had been performed by classical cytometry
technique until 2010 and, thereafter, using high sensitivity
(≥0.01%) fluorescent aerolysin (FLAER)-based assay according
to 2010 International Clinical Cytometry Society (ICCS) PNH
Consensus Guidelines and 2012 Practical PNH Guidelines (14,
15). FLAER/CD33/CD15/CD45 and FLAER/CD59 panels had
been used for white blood cell (WBC) and red blood cell (RBC)
testing, respectively.
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Evaluation of Immunomodulatory and
Inflammatory Cytokines
In a fraction of patients (N = 11) the following cytokines
were evaluated in serum using commercial ELISA kits (High
Sensitivity Elisa kits, Invitrogen by Thermo Fisher Scientific, MA,
USA, human TGF-β elisa kit, Immunological Sciences, Rome,
Italy): interleukin (IL)6, IL10, IL17, tumor necrosis factor (TNF)-
α, interferon (IFN)-γ, and transforming growth factor (TGF)-β.
Cytokine levels were compared with 40 age and sex matched
healthy controls.
Statistical Analysis
Student t–test was used for continuous variables and chi-square
test for categorical ones. Analysis of variance was performed by
using mean, median, ranges and standard errors. Cumulative
incidence of relapse, as well as overall survival, was evaluated by
Kaplan Meyer method.
RESULTS
Demographics and Hematologic
Parameters
Clinical and hematologic features are shown in Table 1: 46%
of patients were older than 60 years of age, male to female
ratio was 0.98, and all AIHA types were represented (wAIHA,
cAIHA, wAIHA+C, mixed and atypical cases). One third of
cases presented severe anemia and hemoglobin levels positively
correlated with LDH > 1.5 x ULN (r = 0.21 p= 0.03), indicating
active intravascular hemolysis, as well as with inadequate
reticulocytosis (i.e., BMRI<121, N = 22, r = 0.19, p = 0.05).
Bone marrow evaluation had been performed in 74 cases and
showed hypercellularity and diserythropoiesis in about half of
cases (52 and 57%, respectively), and reticulin fibrosis (MF-1)
in 42%; the latter displayed reduced BMRI compared with MF-0
patients (107 vs. 137, p = 0.05). Moreover, 63% of patients had
a lymphoid infiltrate, with mainly T or mixed phenotype, not
diagnostic for overt lymphoproliferative syndromes.
AIHA Treatment, Complication and
Outcome
Thirty-nine (39%) of patients required at least one transfusion
during the follow up, and 94% received AIHA treatment
(Table 2). Specifically, 89% were treated with steroids, 71%
responded, and 55% relapsed and required further treatment.
Second line therapy included rituximab (57% with an overall
response rate of 81.5%), splenectomy (7.2% with 75% responsive
cases), and cytotoxic immunosuppressants (20.8%, with a
response in 65% of patients). On the whole, patients received a
median of 2 (range 0–5) therapy lines. Regarding AIHA related
complications, 7% of cases developed acute renal failure, 31% an
infectious episode, 12% experienced a thrombosis (2 pulmonary
embolisms and 10 lower limbs deep venous thrombosis), and 8%
died (3 patients for AIHA-related complications).
TABLE 1 | Clinical and hematologic characteristics of AIHA patients, altogether
and according to PNH positivity.
All patients PNH neg PNH pos
Clinical
characteristics
N = 99 N = 62 N = 37
Median Age y(range) 57 (5–89) 57 (20–85) 63 (5–89)
M/F 49/50 30/32 20/17
Median follow up
m(range)
20 (0–262) 26 (0–205) 24 (2–262)
WAIHA N(%) 37 (38) 27 (43.5) 10 (28.6)
WAIHA IgG+C N(%) 15 (16) 9 (14.5) 6 (17)
CAD N(%) 33 (34) 19 (31) 14 (40)
Mixed N(%) 5 (5) 3 (5) 2 (6)
Atypical N(%) 7(7) 4 (6.5) 3 (8.6)
Median Hb g/dL (range) 7.9 (1.4–13.7) 7.8 (3.5–13.1) 7.9 (1.4–13.7)
Median LDH U/L(range) 451 (150–3,200) 392 (150–1,867) 606 (191–3,200)*
Median LDH ULN
(range)
2 (0–14) 2 (0–7) 2 (1–14)**
Median Ret x103/mmc
(range)
156 (5–574) 151 (5–478) 195 (38–574)
Median BMRI (range) 103 (2–378) 95 (2–305) 128 (18–378)
BMRI<121 N(%) 52 (52) 38 (61) 14 (38)£
Bone marrow
evaluation
N = 74 N = 47 N = 26
Median Cellularity %
(range)
55 (15–100) 55 (20–100) 55 (15–95)
Hypercellularity (%) 38 (51) 24 (51) 14 (54)
Fibrosis MF1 (%) 31 (42) 22 (46) 9 (35)
Dyserythropoiesis (%) 42 (57) 28 (58) 14 (52)
Median lymphoid
infiltrate%(range)
5 (0–75) 5 (0–75) 5 (0–30)
Type of infiltrate B(%) 10 (10) 8 (13) 2 (6)
T(%) 28 (29) 16 (26) 12 (34)
Mixed (%) 23 (24) 16 (26) 7 (20)
PNH paroxysmal nocturnal hemoglobinuria; CAD cold agglutinin disease; WAIHA
warm autoimmune haemolytic anemia; Hb hemoglobin; Ret reticulocytes; LDH lactate
dehydrogenase; ULN upper limit of normality; BMRI bone marrow responsiveness index.
*P = 0.005; **P = 0.03; £P = 0.01.
PNH Clone Analysis and Description of
Two Peculiar Cases
Thirty-seven cases (37%) showed a PNH clone on granulocytes.
Five patients had been tested before FLAER era (2 showed a
PNH clone size of 0.2% on granulocytes) and 3 of them were
re-evaluated thereafter (all PNH negative). PNH positive AIHA
showed increased LDH levels as compared to negative ones (p
= 0.005) and mostly adequate reticulocytosis (BMRI>121 in
62% vs. 39% in PNH negative, p = 0.01). Other hematologic
features, including AIHA type, were comparable among the
two groups (Table 1). Notably, relapse free survival (RFS) after
steroids was slightly shorter in PNH positive than in negative
cases, whilst no other differences in treatment choice or response
rate were noted. In PNH positive patients, median clone size on
granulocytes was 0.2% (0.03–85). Only two patients displayed
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TABLE 2 | Treatments and outcome of AIHA patients, altogether and according to
PNH positivity.
All patients PNH neg PNH pos
Treatment and outcome N = 99 N = 62 N = 37
First therapy line N(%) 96 (96) 61(98) 35 (94)
Second therapy line N(%) 57 (57) 35 (56) 20 (54)
Third therapy line or > N(%) 31 (31) 19 (31) 12 (32)
Median RFS days (range) 539 (25–6,014) 700 (25–6,014) 338 (42–3,483)
Evans (%) 14 (14) 6 (10) 7 (19)
Acute renal failure (%) 7 (7) 6 (10) 1 (3)
Infections (%) 31 (31) 19 (31) 10 (29)
Thrombosis (%) 12 (12) 7 (11) 5 (14)
Death (%) 8 (8) 3(5) 5(14)
Median OS m(%) 25 (0–262) 26 (0–205) 24 (2–62)
OS, overall survival; RFS, relapse free survival.
a PNH clone >10% and both showed LDH levels >1.5xULN.
The first patient was a 40-year-old man, initially diagnosed
with primary wAIHA that was effectively treated with steroids
and rituximab; subsequently a PNH clone 16% was detected
and he developed a severe and fatal Pneumocystis jerovecii
pneumonia (Figure 1A). The second patient was a 65-year-
old lady diagnosed with very severe wAIHA responsive to
steroids with amelioration of anemia. However, LDH levels
were persistently high, and a lower limb venous thrombosis
occurred. Re-evaluation of other causes of hemolysis, including
congenital, toxic, mechanical, and infective forms, demonstrated
a PNH clone 85% on granulocytes (Figure 1B). The patient
started low molecular weight heparin, but after discharge
discontinued treatment. She presented 2 months later with a
massive pulmonary embolism and very severe haemolytic anemia
(Hb 4.2 g/dL and LDH 5.7xULN). DAT tube was still positive
and PNH clone unchanged. She restarted anticoagulation, was
transfused, and commenced eculizumab. Since these two cases
resemble PNH (subclinical and haemolytic type, respectively),
were not included in further correlations.
Cytokine Studies
Figure 2 shows cytokine levels in PNH positive and PNH
negative AIHA patients, in age and sex matched controls (N =
40), and in a cohort of classic hemolytic PNH cases (N = 28).
IFN-γ and IL-17 levels were lower in PNH positive vs. PNH
negative AIHA (0.3 ± 0.2 vs. 1.33 ± 2.5; 0.15 ± 0.3 vs. 3,7 ± 9.1,
respectively, p = 0.07 for both), whilst IL-6 and IL-10 were not
significantly different in the two groups.
As compared to healthy controls, IFN-γ and IL-17 levels were
reduced in PNH positive AIHA, similarly to what observed in
patients with classical PNH. Conversely, IL-6 and IL-10 were
greater compared to healthy volunteers. Concerning TNF-α
and TGF-β levels, no clear differences emerged among groups.
Focusing on PNH positive AIHA patients, IFN-γ positively
correlated with reticulocytes (r = 0.52, p = 0.01) whilst IL-17
showed a negative correlation (r=−0.4, p= 0.04). Similar results
were observed for the bone marrow responsiveness index (r =
FIGURE 1 | Clinical course of two patients (A,B) with PNH/AIHA association
and a clone size>10%. Hb, continuous line; LDH, dotted line; gray area,
prednisone therapy; arrows, rituximab 375 mg/sm/week for 4 weeks; LMWH,
low molecular weight heparin; thrombosis, DVT, deep venous thrombosis; PE,
pulmonary embolism; cross indicates death.
0.69 for IFN-γ, p = 0.002 and r = −0.40 for IL-17, p = 0.04).
IL-6 levels and TGF-β positively correlated with clone size (r =
0.35, p = 0.007, and r = 0.38, p = 0.05, respectively), as well as
with LDH values (r = 0.69, p = 0.0003, and r = 0.34, p = 0.07,
respectively). Finally, TNFα levels showed a negative correlation
with clone size (r =−0.4, p= 0.03).
DISCUSSION
In this study we showed for the first time the presence of a PNH
clone in about one third of 99 consecutive AIHA patients. Almost
all cases displayed a small clone (<10%) considered the hallmark
of subclinical PNH according to IPIG classification (8, 10). Two
patients showed a greater clone size and were therefore diagnosed
as PNH associated with AIHA. This association has not been
previously described and should be considered when the patient
is referred for hemolytic anemia. In fact, thrombotic events
are known to occur in about 10% of active AIHA, whilst the
frequency is far higher (about 40%) in classic hemolytic PNH
(8, 16). Of note, in one of the two AIHA/PNH patients, a severe
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FIGURE 2 | cytokine levels in PNH positive and PNH negative AIHA patients, in age and sex matched controls (N = 40), and in a cohort of classic hemolytic PNH
cases (N = 28). IFN-γ and IL-17 levels were lower in PNH positive versus PNH negative AIHA (p = 0.07 for both). No significant p values were obtained. TNF-α and
TGF-β levels are not shown into the figure; their values were (mean ± SD): TNF-α 0.2 ± 0.2 pg/mL in PNH+AIHA, 0.2 ± 0.1 pg/mL in PNH-AIHA, 0.23 ± 0.29 pg/mL
in classic PNH, and 1.3 ± 0.9 pg/mL in healthy controls. TGF-β 3,249 ± 1,570 pg/mL in PNH+AIHA, 3,295 ± 1,697 pg/mL in PNH-AIHA, 21,010 ± 602 pg/mL in
classic PNH, and 3,160 ± 1,884 pg/mL in healthy controls. *represent outlier values.
thrombotic event occurred soon after the discontinuation of
anticoagulant prophylaxis.
An interesting point is the clinical significance of small PNH
clones in the remaining AIHA studied patients. It is known that
small PNH clones are present in more than 50 and 20% of
patients with aplastic anemia or hypoplastic MDS, respectively
(8, 11, 16). Their clinical significance is still a matter of debate,
although in various series an association with a deeper cytopenia,
increased LDH levels, and thrombotic tendency have been
demonstrated in PNH positive cases (11). Moreover, a better
response to immunosuppressive treatment was reported in this
group, stressing the link between PNH clone emergence and
immune mediated bone marrow failure. Among the hypothesis
of PNH clone selection in the context of bone marrow failure,
it has been reported that GPI molecules may be the target
of the autoimmune attack; therefore, GPI negative stem cells
are spared and may further expand through still unknown
mechanisms, including additional mutations and environmental
factors (8, 9, 16). Our results showed that PNH positive AIHA
cases had greater LDH levels, suggesting a higher hemolytic
pattern and possibly an increased thrombotic risk, although the
number of cases and the follow up may be insufficient to draw
definitive conclusions. As regards therapy outcome, no clear
associations have been demonstrated with PNH positivity in this
AIHA cohort. Another feature of PNH positive AIHAs is their
better bonemarrow compensatory response compared with PNH
negative cases. Consistently, hemoglobin values were comparable
between the two groups, in spite of the more marked hemolytic
pattern observed in the former.
On the whole, despite the few clinical correlations found
possibly due to the small sample size and relative short follow-
up, PNH clone testing may be included in the initial work
up of AIHA to either assess the presence of the two diseases
requiring different and specific therapy. Moreover, PNH
clone testing is advisable in complex cases with inadequate
response to AIHA-specific therapy and with persistent
hemolytic activity.
In the attempt to investigate the physiopathology underlying
the emergence of PNH clones in AIHA, we tested several
immunomodulatory and inflammatory cytokines. PNH positive
AIHA patients showed an immunological signature distinct
from negative cases, with reduced levels of IFN-γ and IL-
17. The former is a classic T-helper 1 cytokine involved
in the autoimmune attack against bone marrow precursors
typical of aplastic anemia (3) and reported elevated also in
AIHA. Likewise, IL-17, a cytokine known to amplify the pro-
inflammatory and autoimmune response, has been reported
elevated in the same settings (17–19). In our study, PNH
positive AIHA showed a Th1 profile more similar to hemolytic
PNH than to “classic” (PNH negative) AIHA, suggesting that
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these small clones might mitigate Th1 response. On the
contrary, Th2 cytokines levels, i.e., IL-6 and IL-10, were not
different in PNH positive and negative AIHA cases. This
finding suggests that Th2 signature, the hallmark of humoral
autoimmunity, is particularly strong in AIHA and is not
influenced by the presence of a small PNH clone. Although
these data are preliminary and would need further ad-hoc
studies, it is tempting to speculate that the detection of a
small PNH clone in AIHA reveals the presence of a wider
spectrum of immunologic mechanisms involved in pathogenesis
of the disease compared with PNH-negative AIHAs. In fact,
in the PNH-positive AIHAs the immunologic signature ranges
from overt antibody mediated autoimmunity against peripheral
erythrocytes to a “central” autoimmune attack to bone marrow
precursors. As a matter of fact, PNH clones, in the context
of AA, are thought to be “surviving clones” spared after
autoimmune attack against hematopoietic stem cells (8, 9);
similarly, autoimmunity against erythroid precursors has been
demonstrated in AIHA (3). Whether the emergence of PNH
clones in AIHA is related to coexisting immune-mediated
bone marrow failure and/or represents a favorable response to
bone marrow stress related to acute hemolysis would require
further investigation.
In conclusion, our data suggest testing PNH clones in
AIHA since their prevalence is not negligible. Moreover, PNH
positivity correlates with a prominent hemolytic pattern and
may confer a higher thrombotic risk. Finally, cytokine patterns
of PNH positive and negative AIHAs may give hints about the
pathogenesis of highly hemolytic AIHA.
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